CN109022435B - Conditional induction mouse spermatogonium Tet3 gene knockout cell line and construction method thereof - Google Patents
Conditional induction mouse spermatogonium Tet3 gene knockout cell line and construction method thereof Download PDFInfo
- Publication number
- CN109022435B CN109022435B CN201810801881.5A CN201810801881A CN109022435B CN 109022435 B CN109022435 B CN 109022435B CN 201810801881 A CN201810801881 A CN 201810801881A CN 109022435 B CN109022435 B CN 109022435B
- Authority
- CN
- China
- Prior art keywords
- tet3
- mouse
- sgrna
- gene
- cell line
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention belongs to the technical field of genetic engineering, and relates to a SgRNA guide sequence for knocking out a mouse Tet3 gene, a conditionally-induced mouse spermatogonium Tet3 gene knockout cell line, a construction method and application thereof, wherein a gene editing off-target effect is an important aspect which puzzles the application of a gene editing technology, a Tet3 gene target point obtained by screening the patent is a target point of a unique target sequence screened out of the whole mouse genome, and no other similar sequences exist in the genome, therefore, no off-target effect exists theoretically, and the inducible knockout method is adopted to timely close the expression of the Cas9 protein and effectively prevent off-target generation, after 24h of Dox addition, the mouse spermatogonial cell genome is knocked out by more than 97%, and before and after Dox induction, the mouse spermatogonial cell genome is taken as a good test group and a good control group, so that the cell line and the method established by the invention can be widely applied to Tet3 and other gene function researches.
Description
Technical Field
The invention belongs to the technical field of genetic engineering, and particularly relates to a SgRNA guide sequence for knocking out a mouse Tet3 gene, a conditionally-induced mouse spermatogonium Tet3 gene knock-out cell line and a construction method thereof.
Background
The Tet family (Tet1, Tet2 and Tet3) is one of the important ways of epigenetic regulation by oxidizing 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC) to demethylate genomic DNA. Tet family-mediated methylation regulation involves many aspects of stem cell self-renewal, differentiation, reprogramming and carcinogenesis, and different Tet family members are shown to act on specific cell populations.
Research shows that Tet1/2 is highly expressed in mouse embryonic stem cells (mESCs), and the expression of a pluripotent factor (such as Oct 4) can be reduced by down-regulating the expression of Tet1/2, so that the differentiation of the mESCs is promoted; tet1/3 plays an important role in the self-renewal and differentiation of neural stem cells, mice with a Tet1 knockout show the characteristics of long-term depression and memory loss, and Tet3 with mESCs knockout weakens the capacity of differentiating the mESCs into the neural cells; tet2 has important significance for the maintenance of the self renewal and differentiation of hematopoietic stem cells, and the reduction of the expression of Tet2 can promote the proliferation of the hematopoietic stem cells, but weaken the differentiation capability and promote the transformation of the hematopoietic stem cells into tumors; deletion of Tet2 expresses the ability of myocytes to lose differentiation into myocytes.
Studies have found that 5-mC and 5-hmC levels in the male sperm genome increase on average 1.76% and 5% per year with age, reflecting an increase in variability in sperm DNA. In the development process of mouse sperms, the expression level of 5-hmC is dynamically changed, so that the expression level in the mouse spermatogonium which begins to differentiate is the highest; expression levels decreased dramatically after spermatocytes appeared. And Tet3 expression is high in mouse spermatogonial stem cells and mouse testis tissues, while Tet1/2 is weak, which shows that Tet3 is probably a main regulatory molecule of a Tet family in a sperm development process, after differentiation of primordial germ stem cells, the expression level of Tet1/2 is reduced, an imprinting mode begins to be established, and Tet3 shows a high-level expression state, which indicates that Tet3 can play an important role in maintaining the imprinting mode of a male animal. Whether Tet3 regulates the methylation of mouse spermatogonial stem cell paternal imprinting genes and further controls the sperm development is yet to be proved by research.
Tet3 shows an important role in the development of nerves and reproduction, becomes a hot spot of the research of related apparent molecular mechanisms, and provides important value for the deep research of the functions of the Tet3 in the treatment and prevention of related diseases. In addition, the existing gene editing system comprising CRISPR-Cas9 does not well solve the off-target problem, and is an important restriction aspect influencing the application. The cell line model has wide scientific research and application prospect.
Disclosure of Invention
Based on the situation, in order to overcome the defects of the prior art, the invention provides a SgRNA guide sequence for efficiently knocking out a mouse Tet3 gene, a conditionally-induced mouse spermatogonium Tet3 gene knock-out cell line and a construction method thereof.
In order to realize the purpose of the invention, the invention adopts the following technical scheme:
on one hand, the invention provides a SgRNA guide sequence for knocking out a mouse Tet3 gene, wherein the SgRNA guide sequence has a sequence shown in SEQ ID NO: 1, or a nucleotide sequence represented by the formula (I).
In another aspect, the invention also provides an expression vector containing the SgRNA guide sequence. In a preferred embodiment, the expression vector is pLVX-EGFP-mU6-Tet 3-SgRNA. As a more preferred embodiment, the expression vector has the sequence of SEQ ID NO: 2, or a nucleotide sequence shown in the figure.
On the other hand, the invention also provides a CRISPR-Cas9 expression system for knocking out a mouse Tet3 gene, which comprises the expression vector and a transcription vector of Cas9 protein.
In another aspect, the invention also provides a preferred mouse conditional knockout vector system comprising the SgRNA targeting sequence or expression vector or expression system described above.
On the other hand, the invention also provides application of the SgRNA guide sequence or the expression vector or the expression system or the vector system in preparing the mouse cell with the Tet3 gene knocked out.
In another aspect, the present invention provides a method for conditionally inducing a mouse Tet3 gene knockout, comprising the steps of:
(1) pmU6-gRNA, Addgene 53187 and pLX-SgRNA-EGFP vectors are respectively used as templates, and the sequences shown in SEQ ID NO: 5-6 and SEQ ID NO: 7-8 are primers, and an mU6 fragment and a Tet3-SgRNA fragment are obtained through amplification; using mU6 fragment and Tet3-SgRNA fragment as templates, and obtaining the sequence shown in SEQ ID NO: 5 and SEQ ID NO: 8, performing overlapped PCR amplification by using primers to obtain mU6-Tet3-SgRNA fragments;
(2) the XhoI and NheI double-enzyme digestion mU6-Tet3-SgRNA fragments to obtain mU6-Tet3-SgRNA viscous terminal fragments, then the viscous terminal fragments are connected into a pLVX-EGFP-hU6-SgRNA vector framework with hU6-SgRNA sequences removed, and the pLVX-EGFP-mU6-Tet3-SgRNA slow virus vector is obtained through transformation and construction;
(3) purifying and packaging the pLVX-EGFP-mU6-Tet3-SgRNA lentiviral vector obtained in the step (2) to obtain a lentivirus carrying Tet3-SgRNA-EGFP, and infecting the lentivirus with Tet-on to regulate and express a Cas9 expression spermatogonial cell line, so as to construct and obtain the conditionally induced mouse spermatogonial Tet3 gene knockout cell line.
On the other hand, the invention also provides a mouse spermatogonium Tet3 gene knockout cell line prepared by the method.
Compared with the prior art, the invention has the following beneficial effects:
1. according to the invention, mouse spermatogonium is taken as a research object, a cell line for knocking out mouse spermatogonium Tet3 gene by Dox induction is constructed by combining the CRISPR/Cas9 system, the result shows that after induction, Tet3 gene in cell genome can be cut by 97%, and cutting does not occur before induction, the cell line is a cell model for researching Tet3 regulation and control reproductive development, and can be applied to scientific research and drug research and development, and due to good effect and high repeatability of cell model establishment, a thought can be provided for related drug development.
2. The invention relates to an induced knockout scheme, particularly designs and constructs a Tet3 knockout vector of a mouse, applies an mU6 promoter, adds green fluorescent protein, and facilitates the observation of the result of the invention, the knockout target point designed and screened is the only site established in the genome of the mouse, similar or identical target point sequences do not exist in the genome of the mouse, off-target effect does not exist, and meanwhile, the test result shows that the knockout efficiency reaches more than 97 percent after Dox induction, and the operability is very strong.
Drawings
FIG. 1 is a flow chart of the method for establishing a conditional induced mouse spermatogonium Tet3 knockout cell line in example 1 of the present invention;
fig. 2 shows the screening results of stably transfected Cas9 spermatogonial cell line in example 1 of the present invention, wherein a: a single cell clonal colony stably transfected with the Cas9 gene; b: stably transfected Cas9 cells were passaged in large numbers;
FIG. 3 shows the steps of constructing the pLVX-EGFP-mU6-SgRNA vector in example 1 of the present invention, wherein: a: a Tet3 target point prediction result pattern diagram; b, mU6-Tet3-SgRNA sequence; c: amplifying an mU6 fragment (390bp) and an SgRNA fragment (177 bp); d: obtaining mU6-SgRNA (549bp) fragments through overlapping PCR; e: constructing a vector map of pLVX-EGFP-mU 6-SgRNA;
FIG. 4 shows the screening results of Tet3-SgRNA stable cell line in example 1 of the present invention, wherein A: 293FT cells; b: observing the result of the 293FT cell transfected with Tet3-SgRNA and packaged plasmid for 48h by using a fluorescence microscope; c: establishing a cell line for stably expressing Tet 3-SgRNA;
FIG. 5 shows the results of the establishment and detection of the conditionally-induced Tet3-KO spermatogonial cell line in example 1 of the present invention, wherein A-B: white light and fluorescence (EGFP) observations of Tet3-KO spermatogonium after induction, respectively; c: before and after Dox induction, Tet3-KO genome sequencing analysis results; d: tet3-KO efficiency analysis (97%).
FIG. 6 the target sequence is unique site in the mouse genome, no similar or identical sequence exists, which indicates that the target is reliable and no off-target effect exists (Blast result using ENSEMBL database).
Detailed Description
The invention is further described below with reference to the drawings and specific examples, which are not described for prior art. Specific examples of the present invention are given below, but the examples are only for the purpose of further elaborating the present invention and do not limit the claims of the present invention. The reagents and starting materials used in the following examples were all commercially available unless otherwise specified.
Example 1
Please refer to fig. 1, which is a flowchart of a method for establishing a cell line for conditionally inducing Tet3 knockout of mouse spermatogonium according to the present invention, specifically comprising the following steps:
1) screening of spermatogonial cell line stably expressing eSPcas9 Gene
The packaged lentivirus (Addgene) carrying the eSPcas9 gene is used for infecting a spermatogonial cell line, and finally, a monoclonal cell colony (shown as a figure 2A) is obtained by screening, and a large number of seed cells (shown as a figure 2B) are finally obtained for later researches.
2) pLVX-EGFP-mU6-Tet3-SgRNA vector construction
Referring to the Ensembl database Tet3 gene sequence (NM _183138), according to the webpage SgRNA target prediction tool: http:// www.broadinstitute.org/rnai/public/analysis-tools/sgrn-design-v 1, predicted target sequence (GGAGCTCATCCGGCAATTTG) (SEQ ID NO: 1) (FIG. 3A, located downstream of the first exon ATG); applying pLVX-EGFP-hU6-SgRNA vector (addge) to mouse cells, changing the human hU6 promoter (hU6,266bp) into the mouse mU6 promoter (mU6,316bp) (as shown in figure 3B), firstly amplifying mU6 fragment (390bp) and SgRNA fragment (177bp) (the primers have added enzyme cutting sites and design overlapping parts; as shown in figure 3C); then mU6-Tet3-SgRNA (549 bp; see FIG. 3D) was obtained by overlap PCR; the method comprises the following specific steps:
respectively taking (pmU6-gRNA, Addgene 53187) and pLX-SgRNA-EGFP plasmids as templates, respectively amplifying an mU6 fragment and a Tet3-SgRNA fragment respectively at the upstream of a first section of mU6, the downstream of a first section of mU6, the upstream of a second section of Tet3-SgRNA and the downstream of a second section of Tet3-SgRNA (Table 1), wherein a PCR system (Table 1) comprises the following steps:
TABLE 1 first and second fragment amplification reaction systems
Secondly, mU6+ targeting SgRNA fragments are amplified by an overlapping PCR method, and the PCR reaction system is the same as the above table 1.
The PCR reaction procedure is as in table 2:
TABLE 2 PCR reaction procedure
The obtained PCR product was subjected to 1.3% agarose Gel electrophoresis and then Gel-recovered using the magenta Hipure Gel Pure DNA Mini Kit (D2111-03).
Thirdly, obtaining a promoter mU6-Tet3-SgRNA sequence by an overlapping PCR method, and taking the upstream of the first section of mU6 and the downstream of the second section of Tet3-SgRNA as amplification primers. The reaction system is shown in the following table 4:
TABLE 3 pLX-mU6-Tet3-SgRNA-EGFP vector construction primers TABLE
TABLE 4 overlapping PCR reaction systems
Setting PCR reaction conditions according to requirements, carrying out 1.3% agarose gel electrophoresis on a PCR product after the reaction is finished, recovering gel to obtain a fusion PCR product mU6-Tet3-SgRNA fragment, measuring the concentration by an ultraviolet spectrophotometer, and storing at-20 ℃.
2) Construction of pLVX-EGFP-mU6-Tet3-SgRNA plasmid
The mU6-Tet3-SgRNA fragment is subjected to double enzyme digestion of XhoI and NheI, reaction is carried out for 2h at 37 ℃, then mU6-Tet3-SgRNA cohesive end fragments are recovered, then the mU6-Tet3-SgRNA cohesive end fragments are connected into a pLVX-EGFP-hU6-SgRNA vector framework with hU6-SgRNA sequences removed, Takara T4 DNA Ligase connection kit (D2011A) is used for connection for 3h at 16 ℃, and after positive bacteria are determined by transformation and bacteria liquid PCR and sequencing, a pLVX-EGFP-mU6-Tet3-SgRNA slow virus vector with the length of 8321bp (shown in figure 3E and SEQ ID NO: 2) is successfully constructed.
3) pLVX-EGFP-mU6-Tet3-SgRNA virus packaging and selection of stable cell line
Mixing the constructed pLVX-EGFP-mU6-Tet3-SgRNA lentiviral vector and virus packaging plasmids (pMD2.G and psPAX2) according to a certain proportion, and transfecting 293FT cells growing to 60-70% confluence (figure 4A); after transfection for 48h, the transfection efficiency and the quality and the existence of the virus package were evaluated, and the vector transfection efficiency was high as shown in the results (FIG. 4B); the purified virus liquid carrying the Tet3-SgRNA sequence is infected with a Tet-on expression Cas9 expression spermatogonial cell line (figure 4C), and finally the stably expressed stably-transferred spermatogonial cell line with two vectors of Cas9 and Tet3-SgRNA-EGFP is obtained.
The lentivirus packaging plasmid and the shuttle plasmid are purified by the following method:
because the concentration of the extracted plasmid can not reach the requirement of the concentration of the plasmid in the lentiviral package, further purification is needed, and the specific steps are as follows:
(1) 1/10 volumes of 3M sodium acetate were added and mixed well.
(2) Adding 2.5 times volume of pre-cooled anhydrous ethanol, mixing, and standing at-20 deg.C for 30-60 min.
(3) Centrifuging at 4 deg.C and 12000rpm for 10min, recovering precipitate, and dissolving with 0.5-1mL precooled 75% ethanol;
(4) centrifuge at 12000rpm for 10min at 4 ℃ and gently aspirate the supernatant.
(5) Vacuum drying or room temperature drying, dissolving precipitate with sterile water 50-100 μ L, and storing at-20 deg.C.
The lentivirus packaging method comprises the following steps:
(1)293FT cells plating: is 10cm in advance one day2Culturing 293FT cells in a culture dish, culturing in a 10% 293FT cell culture medium, and infecting when the cell contact reaches 70-80%;
(2) when infection, a clean 1.5mL centrifuge tube was taken, and 300. mu.L DMEM was added, as well as the lentivirus packaging plasmids pSPAX2, pMD2.G and shuttle plasmids (Cas9 or pLVX-EGFP-mU6-Tet3-SgRNA), each using 3.5. mu.g, 10.4. mu.g and 10. mu.g, respectively. Adding 60 μ L Transfection Reagent Attracene Transfection Reagent (Qiagen), mixing well with pipette, standing at 15-25 deg.C for 10-15 min;
(3) washing cells twice by PBS, adding 6mL of 2% 293FT cell culture medium, and dropwise adding the mixed solution;
(4) culturing in 37 deg.C cell culture box for 6 hr, removing culture medium, culturing in 2% 293FT cell culture medium to maintain cell activity, culturing at 37 deg.C with 5% CO2Culturing in an incubator;
(5) the virus stock solution is collected for 48 and 72 hours respectively, centrifuged by a slow speed centrifuge at 2000rpm for 3min, the supernatant is filtered by a 0.45 mu m filter and is marked to be put in a refrigerator for storage at 4 ℃.
The lentivirus infection method comprises the following steps:
(1) resuscitating the mouse spermatogonium preserved by liquid nitrogen, inoculating into a cassette bottle, and placing at 37 deg.C and 5% CO2Culturing in an incubator;
(2) after the cells grow stably, passage is carried out, and a proper amount of cells are inoculated into a new cassette bottle;
(3) when the cells grow to about 60-80% of the bottom surface of the card bottle, washing for 2 times by PBS;
(4) 5mL of filtered pLVX-EGFP-mU6-Tet3-SgRNA lentivirus stock solution is added with 5 mU L of Polybrene with the concentration of 10 mU g/mL and 500 mU L of FBS to be cultured for 12h, and then the solution is changed;
(5) after 24h, the virus liquid is replaced by the complete culture medium for continuous culture;
(6) changing the liquid in a full amount every day, and needing to be tapped and washed by PBS during the liquid changing process;
(7) after the cell line is screened and stabilized, the cell is frozen and stored by a fluorescence microscope, and the result of the transgene is further detected.
4) Establishment and analysis of inducible Tet3-KO cell line
Stably transferring the cells into spermatogonia of two vectors of Cas9 and Tet3-SgRNA-EGFP, screening and passaging; finally obtaining a stable cell line with the in vitro passage frequency of more than 30 generations; the cell line sustained Expression (EGFP) (fig. 5B);
culturing the stable spermatogonia by adding doxycycline (Dox), culturing for 24-72h, and extracting a part of the genome. And using the genome as a template, designing primers for knocking out two sides of the Tet3 gene to amplify, amplifying the length to 440bp, sending to a worker for sequencing, and carrying out primary analysis to see whether a sequencing result has a set peak or not.
TABLE 5 Tet3 Gene knockout detection primer sequences
By adding doxycycline (Dox) for induction, the Tet3 gene was knocked out after induction by sequencing analysis, while the cells before induction showed no knock-out, and both forward and reverse sequencing showed a set of peaks (FIG. 5C), indicating that the Tet3 gene on the homologous chromosome of the cells was knocked out and the cells showed homozygous cell lines.
To further understand the knockout efficiency of Tet3 gene, the amplified fragment was ligated with T vector (pMD)TM18-T Vector). The operation method comprises the following steps:
(1) prepare solutions in PCR tubes (table 6);
TABLE 6 preparation of solution reagent usage
(2) Adding 5 mu L of Solution I;
(3) placing the PCR tube in a thermostat, and reacting for 3h at 16 ℃;
(4) melting 100 μ L of competent cell DH5 α on ice, adding the solution after 3h, mixing gently, and standing on ice for 30 min;
(5) heat shocking at 42 deg.C for 42-60s, and rapidly placing in ice for 1-2 min;
(6) adding 300 μ L LB culture medium, culturing at 37 deg.C and 150rpm for 1 h;
(7) 100 mu L of the bacterial liquid is dripped on a culture medium plate with resistance ampicillin, is evenly smeared and is cultured in a temperature of 37 ℃.
After about 12 hours, 24 single-clone cells were gently picked up with a pipette tip and put into 24 tubes of a centrifuge tube containing 1mL of LB medium to which resistant ampicillin was added, fixed on a shaker, and then cultured at 37 ℃ and 150rpm for 3 hours. Then, M13 upstream and downstream primers (Table 7) are used, the no-load amplification length is 140bp, bacteria liquid PCR detection is carried out, the residual bacteria liquid with the correct strip length is sent to the sequencing, and the gene knockout efficiency is calculated according to the sequencing result.
TABLE 7 upstream and downstream sequences of M13
The knock-out efficiency was shown to be above 97% by molecular cloning combined with sequencing analysis (FIG. 5D), and the results of these data confirm that a conditionally-induced Tet3-KO spermatogonial cell line was obtained (FIG. 5).
EXAMPLE 2 screening of target sequences
In the research process, the inventors design a lot of target sequences (see table 8), however, many target sequences are verified through experiments, the target point has no cleavage activity, or the cleavage activity is very low, some target points have off-target effect, some target points have cleavage activity, but also have off-target effect, and finally screening obtains the target sequence 7, the genome is predicted to have no off-target possibility, and simultaneously the site cleavage activity is high, only the target sequence 7 is a unique site in the mouse genome (see fig. 6), and no similar or identical sequence exists, which indicates that the target point is reliable, and no off-target effect exists (using the Blast result of the ENSEMBL database). Thus, the present invention ultimately selects target sequence 7 as the targeting sequence.
TABLE 8Tet3 target sequence screening Table
Sequence listing
<110> institute of Buddha science and technology
<120> conditional induction mouse spermatogonium Tet3 gene knockout cell line and construction method thereof
<141> 2018-07-19
<160> 26
<170> SIPOSequenceListing 1.0
<210> 1
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 1
ggagctcatc cggcaatttg 20
<210> 2
<211> 8321
<212> DNA
<213> Artificial Sequence
<400> 2
ttaatgtagt cttatgcaat actcttgtag tcttgcaaca tggtaacgat gagttagcaa 60
catgccttac aaggagagaa aaagcaccgt gcatgccgat tggtggaagt aaggtggtac 120
gatcgtgcct tattaggaag gcaacagacg ggtctgacat ggattggacg aaccactgaa 180
ttgccgcatt gcagagatat tgtatttaag tgcctagctc gatacataaa cgggtctctc 240
tggttagacc agatctgagc ctgggagctc tctggctaac tagggaaccc actgcttaag 300
cctcaataaa gcttgccttg agtgcttcaa gtagtgtgtg cccgtctgtt gtgtgactct 360
ggtaactaga gatccctcag acccttttag tcagtgtgga aaatctctag cagtggcgcc 420
cgaacaggga cttgaaagcg aaagggaaac cagaggagct ctctcgacgc aggactcggc 480
ttgctgaagc gcgcacggca agaggcgagg ggcggcgact ggtgagtacg ccaaaaattt 540
tgactagcgg aggctagaag gagagagatg ggtgcgagag cgtcagtatt aagcggggga 600
gaattagatc gcgatgggaa aaaattcggt taaggccagg gggaaagaaa aaatataaat 660
taaaacatat agtatgggca agcagggagc tagaacgatt cgcagttaat cctggcctgt 720
tagaaacatc agaaggctgt agacaaatac tgggacagct acaaccatcc cttcagacag 780
gatcagaaga acttagatca ttatataata cagtagcaac cctctattgt gtgcatcaaa 840
ggatagagat aaaagacacc aaggaagctt tagacaagat agaggaagag caaaacaaaa 900
gtaagaccac cgcacagcaa gcggccgctg atcttcagac ctggaggagg agatatgagg 960
gacaattgga gaagtgaatt atataaatat aaagtagtaa aaattgaacc attaggagta 1020
gcacccacca aggcaaagag aagagtggtg cagagagaaa aaagagcagt gggaatagga 1080
gctttgttcc ttgggttctt gggagcagca ggaagcacta tgggcgcagc gtcaatgacg 1140
ctgacggtac aggccagaca attattgtct ggtatagtgc agcagcagaa caatttgctg 1200
agggctattg aggcgcaaca gcatctgttg caactcacag tctggggcat caagcagctc 1260
caggcaagaa tcctggctgt ggaaagatac ctaaaggatc aacagctcct ggggatttgg 1320
ggttgctctg gaaaactcat ttgcaccact gctgtgcctt ggaatgctag ttggagtaat 1380
aaatctctgg aacagatttg gaatcacacg acctggatgg agtgggacag agaaattaac 1440
aattacacaa gcttaataca ctccttaatt gaagaatcgc aaaaccagca agaaaagaat 1500
gaacaagaat tattggaatt agataaatgg gcaagtttgt ggaattggtt taacataaca 1560
aattggctgt ggtatataaa attattcata atgatagtag gaggcttggt aggtttaaga 1620
atagtttttg ctgtactttc tatagtgaat agagttaggc agggatattc accattatcg 1680
tttcagaccc acctcccaac cccgagggga cccttgcgcc ttttccaagg cagccctggg 1740
tttgcgcagg gacgcggctg ctctgggcgt ggttccggga aacgcagcgg cgccgaccct 1800
gggtctcgca cattcttcac gtccgttcgc agcgtcaccc ggatcttcgc cgctaccctt 1860
gtgggccccc cggcgacgct tcctgctccg cccctaagtc gggaaggttc cttgcggttc 1920
gcggcgtgcc ggacgtgaca aacggaagcc gcacgtctca ctagtaccct cgcagacgga 1980
cagcgccagg gagcaatggc agcgcgccga ccgcgatggg ctgtggccaa tagcggctgc 2040
tcagcagggc gcgccgagag cagcggccgg gaaggggcgg tgcgggaggc ggggtgtggg 2100
gcggtagtgt gggccctgtt cctgcccgcg cggtgttccg cattctgcaa gcctccggag 2160
cgcacgtcgg cagtcggctc cctcgttgac cgaatcaccg acctctctcc ccagggggta 2220
ccaccatggc caagcctttg tctcaagaag aatccaccct cattgaaaga gcaacggcta 2280
caatcaacag catccccatc tctgaagact acagcgtcgc cagcgcagct ctctctagcg 2340
acggccgcat cttcactggt gtcaatgtat atcattttac tgggggacct tgtgcagaac 2400
tcgtggtgct gggcactgct gctgctgcgg cagctggcaa cctgacttgt atcgtcgcga 2460
tcggaaatga gaacaggggc atcttgagcc cctgcggacg gtgccgacag gtgcttctcg 2520
atctgcatcc tgggatcaaa gccatagtga aggacagtga tggacagccg acggcagttg 2580
ggattcgtga attgctgccc tctggttatg tgtgggaggg cgagggcaga ggaagtctgc 2640
taacatgcgg tgacgtcgag gagaatcctg gcccagagag cgacgagagc ggcctgcccg 2700
ccatggagat cgagtgccgc atcaccggca ccctgaacgg cgtggagttc gagctggtgg 2760
gcggcggaga gggcaccccc aagcagggcc gcatgaccaa caagatgaag agcaccaaag 2820
gcgccctgac cttcagcccc tacctgctga gccacgtgat gggctacggc ttctaccact 2880
tcggcaccta ccccagcggc tacgagaacc ccttcctgca cgccatcaac aacggcggct 2940
acaccaacac ccgcatcgag aagtacgagg acggcggcgt gctgcacgtg agcttcagct 3000
accgctacga ggccggccgc gtgatcggcg acttcaaggt ggtgggcacc ggcttccccg 3060
aggacagcgt gatcttcacc gacaagatca tccgcagcaa cgccaccgtg gagcacctgc 3120
accccatggg cgataacgtg ctggtgggca gcttcgcccg caccttcagc ctgcgcgacg 3180
gcggctacta cagcttcgtg gtggacagcc acatgcactt caagagcgcc atccacccca 3240
gcatcctgca gaacgggggc cccatgttcg ccttccgccg cgtggaggag ctgcacagca 3300
acaccgagct gggcatcgtg gagtaccagc acgccttcaa gacccccatc gccttcgcca 3360
gatcccgcgc tcagtcgtcc aattctgccg tggacggcac cgccggaccc ggctccaccg 3420
gatctcgcta agaattctag atcttgagac aaatggcagt attcatccac aattttaaaa 3480
gaaaaggggg gattgggggg tacagtgcag gggaaagaat agtagacata atagcaacag 3540
acatacaaac taaagaatta caaaaacaaa ttacaaaaat tcaaaatttt cgggtttatt 3600
acagggacag cagagatcca ctttggcgcc ggctcgagtg tacaaaaaag caggctttaa 3660
aggaaccaat tcagtcgact ggatccggta ccgatccgac gccgccatct ctaggcccgc 3720
gccggccccc tcgcacagac ttgtgggaga agctcggcta ctcccctgcc ccggttaatt 3780
tgcatataat atttcctagt aactatagag gcttaatgtg cgataaaaga cagataatct 3840
gttcttttta atactagcta cattttacat gataggcttg gatttctata agagatacaa 3900
atactaaatt attattttaa aaaacagcac aaaaggaaac tcaccctaac tgtaaagtaa 3960
ttgtgtgttt tgagactata aatatccctt ggagaaaagc cttgtttggg agctcatccg 4020
gcaatttggt tttagagcta gaaatagcaa gttaaaataa ggctagtccg ttatcaactt 4080
gaaaaagtgg caccgagtcg gtgctttttt tctagaccca gctttcttgt acaaagttgg 4140
cattagctag cgctaaccgg tggcgcgtta agtcgacaat caacctctgg attacaaaat 4200
ttgtgaaaga ttgactggta ttcttaacta tgttgctcct tttacgctat gtggatacgc 4260
tgctttaatg cctttgtatc atgctattgc ttcccgtatg gctttcattt tctcctcctt 4320
gtataaatcc tggttgctgt ctctttatga ggagttgtgg cccgttgtca ggcaacgtgg 4380
cgtggtgtgc actgtgtttg ctgacgcaac ccccactggt tggggcattg ccaccacctg 4440
tcagctcctt tccgggactt tcgctttccc cctccctatt gccacggcgg aactcatcgc 4500
cgcctgcctt gcccgctgct ggacaggggc tcggctgttg ggcactgaca attccgtggt 4560
gttgtcgggg aaatcatcgt cctttccttg gctgctcgcc tgtgttgcca cctggattct 4620
gcgcgggacg tccttctgct acgtcccttc ggccctcaat ccagcggacc ttccttcccg 4680
cggcctgctg ccggctctgc ggcctcttcc gcgtcttcgc cttcgccctc agacgagtcg 4740
gatctccctt tgggccgcct ccccgcgtcg actttaagac caatgactta caaggcagct 4800
gtagatctta gccacttttt aaaagaaaag gggggactgg aagggctaat tcactcccaa 4860
cgaagacaag atctgctttt tgcttgtact gggtctctct ggttagacca gatctgagcc 4920
tgggagctct ctggctaact agggaaccca ctgcttaagc ctcaataaag cttgccttga 4980
gtgcttcaag tagtgtgtgc ccgtctgttg tgtgactctg gtaactagag atccctcaga 5040
cccttttagt cagtgtggaa aatctctagc agtacgtata gtagttcatg tcatcttatt 5100
attcagtatt tataacttgc aaagaaatga atatcagaga gtgagaggaa cttgtttatt 5160
gcagcttata atggttacaa ataaagcaat agcatcacaa atttcacaaa taaagcattt 5220
ttttcactgc attctagttg tggtttgtcc aaactcatca atgtatctta tcatgtctgg 5280
ctctagctat cccgccccta actccgccca tcccgcccct aactccgccc agttccgccc 5340
attctccgcc ccatggctga ctaatttttt ttatttatgc agaggccgag gccgcctcgg 5400
cctctgagct attccagaag tagtgaggag gcttttttgg aggcctaggg acgtacccaa 5460
ttcgccctat agtgagtcgt attacgcgcg ctcactggcc gtcgttttac aacgtcgtga 5520
ctgggaaaac cctggcgtta cccaacttaa tcgccttgca gcacatcccc ctttcgccag 5580
ctggcgtaat agcgaagagg cccgcaccga tcgcccttcc caacagttgc gcagcctgaa 5640
tggcgaatgg gacgcgccct gtagcggcgc attaagcgcg gcgggtgtgg tggttacgcg 5700
cagcgtgacc gctacacttg ccagcgccct agcgcccgct cctttcgctt tcttcccttc 5760
ctttctcgcc acgttcgccg gctttccccg tcaagctcta aatcgggggc tccctttagg 5820
gttccgattt agtgctttac ggcacctcga ccccaaaaaa cttgattagg gtgatggttc 5880
acgtagtggg ccatcgccct gatagacggt ttttcgccct ttgacgttgg agtccacgtt 5940
ctttaatagt ggactcttgt tccaaactgg aacaacactc aaccctatct cggtctattc 6000
ttttgattta taagggattt tgccgatttc ggcctattgg ttaaaaaatg agctgattta 6060
acaaaaattt aacgcgaatt ttaacaaaat attaacgctt acaatttagg tggcactttt 6120
cggggaaatg tgcgcggaac ccctatttgt ttatttttct aaatacattc aaatatgtat 6180
ccgctcatga gacaataacc ctgataaatg cttcaataat attgaaaaag gaagagtatg 6240
agtattcaac atttccgtgt cgcccttatt cccttttttg cggcattttg ccttcctgtt 6300
tttgctcacc cagaaacgct ggtgaaagta aaagatgctg aagatcagtt gggtgcacga 6360
gtgggttaca tcgaactgga tctcaacagc ggtaagatcc ttgagagttt tcgccccgaa 6420
gaacgttttc caatgatgag cacttttaaa gttctgctat gtggcgcggt attatcccgt 6480
attgacgccg ggcaagagca actcggtcgc cgcatacact attctcagaa tgacttggtt 6540
gagtactcac cagtcacaga aaagcatctt acggatggca tgacagtaag agaattatgc 6600
agtgctgcca taaccatgag tgataacact gcggccaact tacttctgac aacgatcgga 6660
ggaccgaagg agctaaccgc ttttttgcac aacatggggg atcatgtaac tcgccttgat 6720
cgttgggaac cggagctgaa tgaagccata ccaaacgacg agcgtgacac cacgatgcct 6780
gtagcaatgg caacaacgtt gcgcaaacta ttaactggcg aactacttac tctagcttcc 6840
cggcaacaat taatagactg gatggaggcg gataaagttg caggaccact tctgcgctcg 6900
gcccttccgg ctggctggtt tattgctgat aaatctggag ccggtgagcg tgggtctcgc 6960
ggtatcattg cagcactggg gccagatggt aagccctccc gtatcgtagt tatctacacg 7020
acggggagtc aggcaactat ggatgaacga aatagacaga tcgctgagat aggtgcctca 7080
ctgattaagc attggtaact gtcagaccaa gtttactcat atatacttta gattgattta 7140
aaacttcatt tttaatttaa aaggatctag gtgaagatcc tttttgataa tctcatgacc 7200
aaaatccctt aacgtgagtt ttcgttccac tgagcgtcag accccgtaga aaagatcaaa 7260
ggatcttctt gagatccttt ttttctgcgc gtaatctgct gcttgcaaac aaaaaaacca 7320
ccgctaccag cggtggtttg tttgccggat caagagctac caactctttt tccgaaggta 7380
actggcttca gcagagcgca gataccaaat actgttcttc tagtgtagcc gtagttaggc 7440
caccacttca agaactctgt agcaccgcct acatacctcg ctctgctaat cctgttacca 7500
gtggctgctg ccagtggcga taagtcgtgt cttaccgggt tggactcaag acgatagtta 7560
ccggataagg cgcagcggtc gggctgaacg gggggttcgt gcacacagcc cagcttggag 7620
cgaacgacct acaccgaact gagataccta cagcgtgagc tatgagaaag cgccacgctt 7680
cccgaaggga gaaaggcgga caggtatccg gtaagcggca gggtcggaac aggagagcgc 7740
acgagggagc ttccaggggg aaacgcctgg tatctttata gtcctgtcgg gtttcgccac 7800
ctctgacttg agcgtcgatt tttgtgatgc tcgtcagggg ggcggagcct atggaaaaac 7860
gccagcaacg cggccttttt acggttcctg gccttttgct ggccttttgc tcacatgttc 7920
tttcctgcgt tatcccctga ttctgtggat aaccgtatta ccgcctttga gtgagctgat 7980
accgctcgcc gcagccgaac gaccgagcgc agcgagtcag tgagcgagga agcggaagag 8040
cgcccaatac gcaaaccgcc tctccccgcg cgttggccga ttcattaatg cagctggcac 8100
gacaggtttc ccgactggaa agcgggcagt gagcgcaacg caattaatgt gagttagctc 8160
actcattagg caccccaggc tttacacttt atgcttccgg ctcgtatgtt gtgtggaatt 8220
gtgagcggat aacaatttca cacaggaaac agctatgacc atgattacgc caagcgcgca 8280
attaaccctc actaaaggga acaaaagctg gagctgcaag c 8321
<210> 3
<211> 98
<212> DNA
<213> Artificial Sequence
<400> 3
ccactttggc gccggctcga gtgtacaaaa aagcaggctt taaaggaacc aattcagtcg 60
actggatccg gtaccgatcc gacgccgcca tctctagg 98
<210> 4
<211> 21
<212> DNA
<213> Artificial Sequence
<400> 4
gcgccaccgg ttagcgctag c 21
<210> 5
<211> 23
<212> DNA
<213> Artificial Sequence
<400> 5
tttggcgccg gctcgagtgt aca 23
<210> 6
<211> 22
<212> DNA
<213> Artificial Sequence
<400> 6
aaacaaggct tttctccaag gg 22
<210> 7
<211> 59
<212> DNA
<213> Artificial Sequence
<400> 7
tggagaaaag ccttgtttgg gagctcatcc ggcaatttgg ttttagagct agaaatagc 59
<210> 8
<211> 24
<212> DNA
<213> Artificial Sequence
<400> 8
caccggttag cgctagctaa tgcc 24
<210> 9
<211> 21
<212> DNA
<213> Artificial Sequence
<400> 9
cagaaggaca ggcaccgtta c 21
<210> 10
<211> 23
<212> DNA
<213> Artificial Sequence
<400> 10
atggaagcag gtagttgaga gca 23
<210> 11
<211> 24
<212> DNA
<213> Artificial Sequence
<400> 11
cgccagggtt ttcccagtca cgac 24
<210> 12
<211> 21
<212> DNA
<213> Artificial Sequence
<400> 12
cacacaggaa acagctatga c 21
<210> 13
<211> 21
<212> DNA
<213> Artificial Sequence
<400> 13
gtggtaactg gccgcgggga c 21
<210> 14
<211> 21
<212> DNA
<213> Artificial Sequence
<400> 14
ggcccgccgg acccggtctt c 21
<210> 15
<211> 21
<212> DNA
<213> Artificial Sequence
<400> 15
gcctggtggc cttttcggcc g 21
<210> 16
<211> 21
<212> DNA
<213> Artificial Sequence
<400> 16
gacccctgct ggaggtcccg t 21
<210> 17
<211> 21
<212> DNA
<213> Artificial Sequence
<400> 17
ggacttaccc gaaagcctgt g 21
<210> 18
<211> 21
<212> DNA
<213> Artificial Sequence
<400> 18
gatttgcacc tagtccctcc g 21
<210> 19
<211> 21
<212> DNA
<213> Artificial Sequence
<400> 19
ggacacgtat cgcgcttacc a 21
<210> 20
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 20
ggtacaggcc aggagttccg 20
<210> 21
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 21
gctgctccag ttctgccata 20
<210> 22
<211> 21
<212> DNA
<213> Artificial Sequence
<400> 22
gaatgagatc ccccagcccc a 21
<210> 23
<211> 21
<212> DNA
<213> Artificial Sequence
<400> 23
gatagggtca gggcttgggc g 21
<210> 24
<211> 21
<212> DNA
<213> Artificial Sequence
<400> 24
gttagctgcc ttgaatctcc a 21
<210> 25
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 25
ggctctctag caccattgac 20
<210> 26
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 26
gaatggtgct agagagcccg 20
Claims (5)
1. A SgRNA guide sequence for knocking out a mouse Tet3 gene is characterized in that the SgRNA guide sequence is shown as SEQ ID NO: 1, or a nucleotide sequence represented by the formula (I).
2. An expression vector comprising the SgRNA targeting sequence of claim 1.
3. The expression vector of claim 2, wherein the expression vector is pLVX-EGFP-mU6-Tet 3-SgRNA; the base sequence of the expression vector is shown as SEQ ID NO: 2, respectively.
4. A CRISPR-Cas9 expression system for knocking out a mouse Tet3 gene, which is characterized by comprising the expression vector of any one of claims 2 to 3 and a Cas9 protein expression vector.
5. Use of the SgRNA targeting sequence of claim 1 or the expression vector of any one of claims 2 to 3 or the expression system of claim 4 in the preparation of a mouse cell with a Tet3 gene knockout; the use is for non-disease treatment purposes.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810801881.5A CN109022435B (en) | 2018-07-19 | 2018-07-19 | Conditional induction mouse spermatogonium Tet3 gene knockout cell line and construction method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810801881.5A CN109022435B (en) | 2018-07-19 | 2018-07-19 | Conditional induction mouse spermatogonium Tet3 gene knockout cell line and construction method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109022435A CN109022435A (en) | 2018-12-18 |
CN109022435B true CN109022435B (en) | 2022-05-06 |
Family
ID=64644432
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810801881.5A Active CN109022435B (en) | 2018-07-19 | 2018-07-19 | Conditional induction mouse spermatogonium Tet3 gene knockout cell line and construction method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109022435B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111549032A (en) * | 2020-05-26 | 2020-08-18 | 肇庆学院 | Construction method of inducible spermatogonium Tubb4b gene knockout cell line |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102669057A (en) * | 2011-03-18 | 2012-09-19 | 上海南方模式生物科技发展有限公司 | Genetic modification method for regulating and controlling animal endogenous gene expression |
WO2014172470A2 (en) * | 2013-04-16 | 2014-10-23 | Whitehead Institute For Biomedical Research | Methods of mutating, modifying or modulating nucleic acid in a cell or nonhuman mammal |
CN104694490A (en) * | 2013-12-04 | 2015-06-10 | 徐彦辉 | TET2protein and 5-mC DNA three-dimensional structure and application thereof |
CN104745626A (en) * | 2014-12-19 | 2015-07-01 | 中国航天员科研训练中心 | Rapid construction method and applications of conditional gene knockout animal model |
CN105624194A (en) * | 2016-02-16 | 2016-06-01 | 广东省农业科学院农业生物基因研究中心 | Conditional Cas9 expression induced swine trophoblastic cell line and establishment method and application thereof |
WO2017049166A1 (en) * | 2015-09-17 | 2017-03-23 | Novartis Ag | Car t cell therapies with enhanced efficacy |
CN107523588A (en) * | 2017-08-18 | 2017-12-29 | 深圳大学 | A kind of tetracycline slow virus inducible expression carrier and its method for building up and application |
CN107988257A (en) * | 2017-12-12 | 2018-05-04 | 西北农林科技大学 | Carrier, cell and the method for goat cloning efficiency are improved based on the horizontal modification of donorcells DNA methylation |
US10604759B2 (en) * | 2016-01-15 | 2020-03-31 | City Of Hope | Targeting glioblastoma stem cells through the TLX-TET3 axis |
-
2018
- 2018-07-19 CN CN201810801881.5A patent/CN109022435B/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102669057A (en) * | 2011-03-18 | 2012-09-19 | 上海南方模式生物科技发展有限公司 | Genetic modification method for regulating and controlling animal endogenous gene expression |
WO2014172470A2 (en) * | 2013-04-16 | 2014-10-23 | Whitehead Institute For Biomedical Research | Methods of mutating, modifying or modulating nucleic acid in a cell or nonhuman mammal |
CN104694490A (en) * | 2013-12-04 | 2015-06-10 | 徐彦辉 | TET2protein and 5-mC DNA three-dimensional structure and application thereof |
CN104745626A (en) * | 2014-12-19 | 2015-07-01 | 中国航天员科研训练中心 | Rapid construction method and applications of conditional gene knockout animal model |
WO2017049166A1 (en) * | 2015-09-17 | 2017-03-23 | Novartis Ag | Car t cell therapies with enhanced efficacy |
US10604759B2 (en) * | 2016-01-15 | 2020-03-31 | City Of Hope | Targeting glioblastoma stem cells through the TLX-TET3 axis |
CN105624194A (en) * | 2016-02-16 | 2016-06-01 | 广东省农业科学院农业生物基因研究中心 | Conditional Cas9 expression induced swine trophoblastic cell line and establishment method and application thereof |
CN107523588A (en) * | 2017-08-18 | 2017-12-29 | 深圳大学 | A kind of tetracycline slow virus inducible expression carrier and its method for building up and application |
CN107988257A (en) * | 2017-12-12 | 2018-05-04 | 西北农林科技大学 | Carrier, cell and the method for goat cloning efficiency are improved based on the horizontal modification of donorcells DNA methylation |
Non-Patent Citations (3)
Title |
---|
Tet3 and DNA Replication Mediate Demethylation of Both the Maternal and Paternal Genomes in Mouse Zygotes;Li Shen 等;《Cell Stem Cell》;20141002;第15卷(第4期);摘要、第2页、第5页的方法和补充材料的表S6 * |
TET蛋白的去甲基化机制及其在调控小鼠发育过程中的作用;贾振伟 等;《遗传》;20150131;第37卷(第1期);第34-40页 * |
The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes;TianPeng Gu 等;《Nature》;20110904;第477卷;摘要、第606-609页 * |
Also Published As
Publication number | Publication date |
---|---|
CN109022435A (en) | 2018-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rose | The nucleotide sequence of pACYC177. | |
CN106103699B (en) | Body cell monoploid Human cell line | |
CN100469877C (en) | Method and compositions for directed clonning and subclonning using homologous recombination | |
ES2379368T3 (en) | Method to increase the production of isoprenoid compounds | |
Xin et al. | Application of the genome editing tool CRISPR/Cas9 in non-human primates | |
KR20210031482A (en) | How to achieve high-specificity genome editing | |
Giacalone et al. | CRISPR‐Cas9‐based genome editing of human induced pluripotent stem cells | |
US20220304286A1 (en) | SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF | |
CN109022435B (en) | Conditional induction mouse spermatogonium Tet3 gene knockout cell line and construction method thereof | |
KR20210144816A (en) | Methods for Construction of Chimeric Plasmid Libraries | |
CN110982842B (en) | Design and application of lentivirus expression vector | |
Chilian et al. | CRISPR/Cas9-mediated tissue-specific knockout and cDNA rescue using sgRNAs that target exon-intron junctions in Drosophila melanogaster | |
CN111549032A (en) | Construction method of inducible spermatogonium Tubb4b gene knockout cell line | |
CN106011133A (en) | Small-DNA-molecular-weight standard, and standard plasmid and preparation method thereof | |
CN114836362A (en) | Method for improving immobilized fermentation of escherichia coli by applying fimH (fimH) in quorum sensing dynamic regulation and control system | |
CN112322590A (en) | Recombinant goat pox virus co-expressing B2L and F1L proteins | |
CN114672515B (en) | Transduction plasmid, lentiviral vector system containing transduction plasmid and application of lentiviral vector system | |
Suchy et al. | Genome engineering with Cas9 and AAV repair templates generates frequent concatemeric insertions of viral vectors | |
Bennett et al. | 12 Detection of Insertion/Deletion (Indel) Events after Genome Targeting: Pros and Cons of the Available Methods | |
Kiszka et al. | Autonomous bioluminescence emission from transgenic mice | |
Adlat et al. | Efficient Single Base Editing in Mouse Using Cytosine Base Editor 4 | |
CN115247181A (en) | Kit for preparing nuclear transplantation donor cells of alopecia model pigs and preparation method thereof | |
CN115247180A (en) | Kit and application thereof in construction of recombinant pig cells of hair follicle tissue specific expression human II type 5 alpha-reductase gene | |
KR101663087B1 (en) | Method of producing α-santalene | |
Zheng et al. | Efficient Single Base Editing in Mouse Using Cytosine Base Editor 4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |